Blood test could spare cancer patients from unnecessary chemotherapy
NCT ID NCT06745076
Summary
This study is testing whether a blood test can safely reduce chemotherapy for people with advanced Hodgkin lymphoma. After two initial chemo cycles, patients with no detectable cancer DNA in their blood will receive less total treatment. The goal is to control the cancer while minimizing side effects from unnecessary chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSIC HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope
NOT_YET_RECRUITINGIrvine, California, 92618, United States
Contact
-
Dana-Farber Cancer Institute
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
-
Washington University in St. Louis
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Conditions
Explore the condition pages connected to this study.